Sparrow Pharmaceuticals rings in $50m Series A

Sparrow Pharmaceuticals, an emerging clinical-stage biopharmaceutical company, has raised $50 million in Series A financing.

18 May 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles